Search

2023 DEC 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Researchers at Ankara Bilkent City Hospital reported a case of a 34-year-old male with acute myeloid leukemia who developed Stevens-Johnson syndrome after undergoing allogeneic hematopoietic stem cell transplantation. The patient initially presented with severe cutaneous manifestations, which were initially suspected to be acute graft-versus-host disease or drug eruptions. Treatment with ruxolitinib, in addition to corticosteroids, led to significant clinical improvement, highlighting the challenges in diagnosing and managing such cases post-transplant. The study underscores the importance of rapid intervention and the potential efficacy of JAK inhibitors in steroid-resistant cutaneous GVHD. [Extracted from the article]

A 47-year-old woman developed Stevens Johnson syndrome (SJS) while being treated with tacrolimus for autoimmune haemolytic anaemia. Despite subsequent treatment with methylprednisolone for SJS, she exhibited a lack of efficacy. The woman experienced painful, itchy erythematous patches with targetoid lesions, photophobia, and oral ulcers. After discontinuing tacrolimus and receiving off-label treatment with tofacitinib, she showed rapid improvement within 2 weeks without new lesions. [Extracted from the article]

A 55-year-old woman developed drug-induced autoimmune-like hepatitis (DI-ALH) and drug-induced Stevens Johnson syndrome (DI-SJS) while being treated with levetiracetam for seizures. She had a medical history of hypertension, hyperlipidemia, and type-2 diabetes mellitus. After experiencing right-sided haemiplegia and seizures, she was found to have elevated liver tests and dermatologic abnormalities, which were attributed to the levetiracetam therapy. Following discontinuation of levetiracetam and treatment with methylprednisolone, the woman showed improvement and had normal liver tests and skin conditions at a 6-month follow-up. [Extracted from the article]

A 44-year-old woman developed Stevens-Johnson syndrome while being treated with lamotrigine for anxiety-depressive disorder. She had a history of anxiety-depressive disorder and was also taking alprazolam, mirtazapine, and lorazepam. After developing painful skin lesions affecting oral and genital mucosa, as well as non-painful erythematous lesions on her skin, she was diagnosed with drug-induced Stevens-Johnson syndrome. Following withdrawal of lamotrigine and treatment with corticosteroids, her condition improved within 2 weeks. [Extracted from the article]

A case report published in Reactions Weekly describes a patient who developed Stevens-Johnson syndrome while being treated with doxycycline. The patient's condition was further complicated by severe dry eye disease, leading to minor salivary gland transplantation. Postoperatively, the patient was advised on dietary restrictions and prescribed various medications to manage the symptoms. This study highlights the potential risks associated with doxycycline therapy and the importance of monitoring for adverse reactions. [Extracted from the article]

A 66-year-old man developed Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) while being treated with cotrimoxazole for a urinary tract infection. The man initially experienced symptoms of fluid-filled lesions and fever, which worsened after receiving cotrimoxazole. He was admitted to the ICU due to deranged renal function and received various treatments to manage his condition. Despite initial challenges, he gradually recovered, with his SJS and TEN ultimately attributed to cotrimoxazole. [Extracted from the article]

A 56-year-old man developed Stevens-Johnson syndrome (SJS) while being treated with cemiplimab for squamous cell carcinoma. The SJS manifested as blistering of the mucous membrane and epidermis throughout the lips, along with painful erosions of the oral mucosa. Treatment with IV dexamethasone improved his symptoms, and he was later discharged and continued treatment at home with prednisone. Despite initial improvement, the man experienced reoccurrence of lesions, which were subsequently resolved with treatment. [Extracted from the article]

A retrospective study described 12 patients who developed drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or SJS/TEN overlap while receiving antiepileptic or antibacterial therapy with various medications. The patients experienced adverse drug reactions after 7-14 days of starting treatment and were all admitted to the hospital. The drugs implicated in these severe skin reactions included amoxicillin, azithromycin, ethosuximide, rufinamide, zonisamide, lamotrigine, oxcarbazepine, and cotrimoxazole. [Extracted from the article]

A recent study from the University of Florence focused on toxic epidermal necrolysis (TEN) induced by lamotrigine in a patient with a cerebral cavernous malformation. The research highlighted the importance of early diagnosis and identifying the causative drug to provide appropriate treatment and reduce mortality. The study emphasized the need for advanced supportive care in such cases. For more information, readers can access the full article in Dermatology Reports. [Extracted from the article]

A recent study conducted at the Apollo Institute of Medical Sciences and Research in Andhra Pradesh, India, focused on Griseofulvin-induced Stevens-Johnson Syndrome (SJS), a rare severe cutaneous adverse drug reaction. The research highlighted the importance of vigilance among physicians, especially dermatologists, when prescribing medications like Griseofulvin for fungal diseases to prevent occurrences of SJS in the future. The study emphasized the need for regular patient follow-up and early diagnosis to benefit society. For more information, the full report can be accessed in the Research Journal of Pharmacy and Technology. [Extracted from the article]

Researchers from the Department of Pharmacy published a case study on Stevens-Johnson syndrome, a severe skin reaction often caused by certain medications. The study focused on a 29-year-old woman who developed the syndrome after taking lamotrigine, olanzapine, and sertraline. Prompt identification, discontinuation of the triggering drugs, and supportive therapy led to significant improvement in the patient's condition within 7 days. This research highlights the importance of early detection and management of Stevens-Johnson syndrome. [Extracted from the article]

A 53-year-old man developed Stevens-Johnson syndrome (SJS) after receiving treatment with gentamicin. He presented with fever, extensive rashes, and pain, which was sudden, burning, and severe in nature. The diagnosis of drug-induced SJS was confirmed through microscopic examination, and the patient was treated with systemic steroids. [Extracted from the article]

The article discusses eight case reports of patients who developed cutaneous adverse drug reactions (cADRs) while being treated with allopurinol. These reactions included drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap, and maculopapular-exanthema. Each patient had a specific human leukocyte antigen-B (HLA-B) genotype and single nucleotide polymorphisms, and despite receiving allopurinol, they experienced these adverse reactions. [Extracted from the article]

A retrospective cohort study between 2015 and 2022 described 12 patients who developed Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or SJS-TEN overlap while being treated with various medications. The patients received drugs such as cotrimoxazole, vancomycin, ceftriaxone, and others, leading to different severe skin reactions. Tragically, two patients died due to complications from TEN and SJS caused by vancomycin and piperacillin/tazobactam, respectively. [Extracted from the article]

A 67-year-old woman developed Stevens-Johnson Syndrome while being treated with strontium-ranelate for post-menopausal osteoporosis. The woman experienced painful oral erosions three weeks after starting the medication, with physical examination revealing erosions on her lips, ulceration on buccal mucosa and soft palate, and skin biopsy confirming the diagnosis. Treatment included discontinuation of strontium-ranelate, IV hydrocortisone, oral prednisolone, topical triamcinolone, and antiseptic mouthwash, leading to a positive response. [Extracted from the article]

A 23-year-old woman developed Stevens-Johnson syndrome (SJS) while being treated with penicillamine for gold cyanide intoxication. She presented with fever, painful oral ulcers, and a rash after starting penicillamine treatment. After discontinuing penicillamine and receiving appropriate care, including dexamethasone and levofloxacin, the woman showed significant improvement and was discharged from the hospital with complete resolution of SJS. [Extracted from the article]

A recent study conducted at Chang Gung Memorial Hospital focused on a case of conjunctival squamous metaplasia on amniotic membrane in a patient with Stevens-Johnson syndrome. The 21-year-old female patient experienced painful, blurred vision and was diagnosed with Stevens-Johnson syndrome. Despite receiving treatment with ProKera(R), complications arose, leading to conjunctival biopsy, amniotic membrane removal, and symblepharon release. The study highlights the potential development of conjunctival squamous metaplasia on the amniotic membrane in patients with Stevens-Johnson syndrome, emphasizing the importance of regular monitoring to prevent further complications. [Extracted from the article]

A 19-year-old woman with epilepsy developed Stevens-Johnson syndrome (SJS) after starting treatment with carbamazepine. She had been taking other medications for epilepsy prior to starting carbamazepine. The woman experienced fever, painful sores, blisters, and mucous discharge from her eyes, leading to a diagnosis of SJS. After receiving a combination of medications, her condition improved, and she was discharged after 14 days of treatment. [Extracted from the article]

A recent study conducted at Addenbrooke's Hospital in Cambridge, United Kingdom, focused on predictors of mortality in adults with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The study found that certain factors such as preexisting renal disease, renal involvement, respiratory involvement, diabetes mellitus, sepsis, comorbidities, and time to hospitalization were associated with an increased risk of mortality in these patients. The research suggests that incorporating these factors into mortality prognostication tools may improve outcomes for adults with SJS/TEN. [Extracted from the article]

A systematic review and meta-analysis conducted at Royal North Shore Hospital in St. Leonards, Australia, focused on infectious complications in adults with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The study found that skin infections were the most commonly diagnosed, with Staphylococcus aureus being the most commonly identified organism. The research highlighted the need for further investigation into risk factors and causative organisms for these infections. The study emphasized the importance of closely monitoring and promptly investigating infectious complications during hospitalization for SJS and TEN. [Extracted from the article]

A recent study conducted at Southern Medical University in Guangzhou, China, focused on analyzing skin care methods and outcomes for patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). The study included 41 inpatients and found that early dry powder exfoliation followed by wet dressing care significantly improved skin lesions and reduced hospitalization time. The research suggests that different nursing models should be adopted based on the phase of skin lesion manifestations. This study provides valuable insights for healthcare professionals treating patients with these severe skin conditions. [Extracted from the article]

A 66-year-old woman developed Stevens-Johnson syndrome while being treated with pembrolizumab for paraneoplastic dermatomyositis. She had a history of urothelial cancer and was diagnosed with a local relapse of the tumor. After experiencing extensive skin and mucosal alterations, she was diagnosed with Stevens-Johnson syndrome and received supportive care, leading to resolution of her condition without the need for maintenance or immunosuppressive therapy. She was later scheduled for chemotherapy with carboplatin and gemcitabine. [Extracted from the article]

A 40-year-old man developed eczema herpeticum while being treated with diclofenac and ibuprofen. He presented to the emergency department with worsening symptoms on his neck and face, accompanied by pus oozing from his eyes and ears. After receiving antiviral and antibiotic therapy, along with symptomatic treatment, his symptoms improved, and he was eventually discharged after completing a 14-day course of therapy. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 17-year-old patient [sex not stated] developed Stevens-Johnson syndrome secondary to treatment with lymecycline [indication, route, dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A 61-year-old man developed Stevens-Johnson syndrome (SJS) while being treated with allopurinol for gout. The man presented with rash and fever, which quickly spread across his body. He was hospitalized and treated with fluids, dexamethasone, and prophylactic antibiotics, eventually showing improvement and being discharged after five days. The suspected cause of SJS was determined to be allopurinol, and the patient was prescribed follow-up appointments and medications for his recovery. [Extracted from the article]

A 13-year-old boy developed Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) while being treated with lamotrigine for bipolar disorder. Despite starting with a low dose of lamotrigine, his condition rapidly deteriorated, leading to a life-threatening situation involving 90% of his skin. He was hospitalized, treated with immunosuppressants, and eventually diagnosed with SJS/TEN attributed to lamotrigine. [Extracted from the article]

The article "Carbamazepine/isoniazid: Toxic epidermal necrolysis and stevens-johnson syndrome: 2 case reports" published in Reactions Weekly discusses two cases of patients in South Africa who developed toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) while being treated with carbamazepine and isoniazid, respectively. One patient died as a result of the reaction to carbamazepine, while the outcome for the other patient was not specified. The study highlights the serious nature of these conditions and the importance of monitoring patients for adverse reactions during treatment. [Extracted from the article]

A 61-year-old woman experienced itching and a possible rash while being treated with allopurinol for gout, and later developed Stevens Johnson syndrome (SJS) while on febuxostat for gout. Despite a history of severe gout, she was unable to tolerate allopurinol and developed a rash, leading to the suspicion that febuxostat was the cause of the SJS. After discontinuing febuxostat and receiving treatment in a burn unit, the woman fully recovered and was able to undergo a desensitization process to resume treatment for gout. [Extracted from the article]

Researchers have submitted a patent application for methods to treat ocular surface pain, particularly chronic ocular surface pain, which can significantly impact patients' quality of life. The application involves ocular administration of a specific compound to reduce pain associated with various ocular conditions, such as dry eye disease and corneal neuropathies. The patent application aims to address the unmet need for safe and effective treatments for chronic ocular surface pain when other options have been exhausted. [Extracted from the article]

Researchers at the University of North Carolina Chapel Hill have reported new findings on agminated eruptive melanocytic nevi and nail changes following toxic epidermal necrolysis in a pediatric patient. The study highlights the importance of clinically appropriate follow-up for eruptive melanocytic nevi, as there have been no reports of malignancy in such cases. Further research is needed to better understand the correlation between nail changes and the development of eruptive melanocytic nevi. [Extracted from the article]

A 5-year-old boy developed Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) while being treated with amoxicillin for scarlet fever. Despite receiving immune-globulin, antibacterials, antihistamines, and steroids, the boy showed a lack of efficacy in his treatment. After switching to ciclosporin, the boy's condition stabilized, and he was eventually discharged in good overall condition. [Extracted from the article]

A recent study published in the Journal of Medical Case Reports discusses a case of a 15-year-old boy who developed Stevens-Johnson syndrome due to a coronavirus disease 2019 infection. The boy, of Han Chinese descent, presented with various symptoms including oral ulcers, rash, and ocular pain. Treatment with methylprednisolone, intravenous immunoglobulin, and dermatological care led to a successful recovery without complications. The research highlights the importance of early identification and appropriate management of Stevens-Johnson syndrome in children with coronavirus infections to improve patient outcomes. [Extracted from the article]

A 43-year-old man developed toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) while being treated with aripiprazole for bipolar disorder, type 1, and experienced increased white blood cell count during treatment with methylprednisolone and prednisone for TEN and SJS. His symptoms included a painful diffuse rash, erythematous and scaly rash on various body parts, and blisters with serous fluid drainage. The man was treated with oral prednisone, IV methylprednisolone, and other medications for pain control, eventually being discharged with quetiapine, bacitracin, and gabapentin with improvement in lesions and pain. [Extracted from the article]

A recent scoping review conducted by researchers at the Medical University of South Carolina focused on pediatric necrotizing otitis externa (NOE). The study included 20 articles with a total of 439 patients, revealing that NOE primarily affects children with immunosuppression or severe health conditions. The review emphasized the importance of biopsy and culture in the treatment of pediatric NOE, highlighting the need for further research in this area. The findings suggest that diabetes does not play as significant a role in pediatric NOE compared to adults, with complications such as cranial nerve palsies being more common in children. [Extracted from the article]

A recent report discusses the rare and severe skin conditions known as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions are primarily drug-induced and characterized by extensive skin detachment, which sets them apart from other skin eruptions. The report proposes new diagnostic criteria to improve accuracy and global applicability, as well as explores recent advances in understanding the immunopathogenesis of SJS/TEN. It also addresses current therapeutic approaches and discusses novel strategies targeting specific pathogenic mechanisms. The report emphasizes the need for coordinated efforts across medical fields to develop effective treatments and diagnostic tools for SJS/TEN. [Extracted from the article]

A new report from the Mayo Clinic focuses on the dermatologic implications of immune checkpoint inhibitors (ICIs) in cancer treatment. The study examined the incidence of severe reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with ICIs. The analysis of 158 case reports revealed that SJS/TEN is more common in males and typically occurs at the age of 63. The study emphasizes the importance of vigilant monitoring and personalized risk assessment in oncology practice to optimize patient outcomes and enhance the safety profile of ICIs in cancer therapy. [Extracted from the article]

A 60-year-old woman developed Stevens-Johnson syndrome while being treated with voriconazole for pulmonary aspergillosis. She had been diagnosed with granulomatosis with polyangiitis (GPA)-associated chronic obstructive pulmonary disease (COPD) and was initially treated with methotrexate. After experiencing complications and positive tests for Aspergillus species, voriconazole was replaced with caspofungin, leading to the resolution of the infection. Methotrexate treatment was temporarily halted during the management of the aspergillosis but was later resumed successfully. [Extracted from the article]

A case report from Bali, Indonesia discusses Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are rare skin reactions often triggered by drugs or external agents. SJS affects less than 10% of the body surface area, while TEN affects more than 30%. Cases with involvement between 10-30% are classified as SJS-TEN overlap syndrome. The report describes a 59-year-old male with SJS-TEN overlap, who had taken cotrimoxazole for toxoplasmosis therapy before symptoms appeared. The patient's condition improved with supportive therapy and discontinuation of the suspected drug. The management of SJS-TEN includes stopping the suspected cause and providing supportive symptomatic therapy. [Extracted from the article]

Researchers at the All India Institute of Medical Sciences (AIIMS) in New Delhi have conducted a study on the outcomes of minor salivary gland transplantation for severe dry eye disease secondary to chronic Stevens-Johnson Syndrome. The study, which took place from 2022 to 2023, involved twenty cases and found that the transplantation resulted in improvements in various clinical parameters, including corneal and conjunctival parameters of the ocular surface. The researchers concluded that minor salivary gland transplantation is a viable management option for cases with severe dry eye disease secondary to chronic Stevens-Johnson Syndrome. The study has been peer-reviewed and published in The Ocular Surface journal. [Extracted from the article]

A recent report from Vanderbilt University provides an update on the diagnosis and management of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are severe cutaneous adverse reactions typically caused by drugs in adults. These conditions have high morbidity and mortality rates. The report discusses the challenges faced by physicians in diagnosing and treating SJS/TEN, as well as the progress made in understanding its genetic predisposition and pathogenesis. The research reviews data on the pathogenesis, precipitating factors, presentation, diagnosis, and management of SJS/TEN, focusing on new developments in the past five years. [Extracted from the article]

This document provides information about a clinical trial for a product called Vit-A-Vision, which is an ointment for the eyes. The ointment is intended to relieve symptoms such as burning, irritation, dryness, and tiredness of the eyes. The trial aims to evaluate the effectiveness of Vit-A-Vision in treating dry eye disease. The ointment will be applied daily for at least 30 days, and the study is expected to be completed by April 2025. The trial is currently not recruiting participants. [Extracted from the article]

A recent study conducted at the University of California has reported on the development of esophageal epidermoid metaplasia (EEM) in a pediatric patient after Stevens-Johnson syndrome (SJS). EEM is a rare condition that has not been previously described in SJS and has only been reported once in pediatrics. The study suggests that pediatric patients presenting with dysphagia after SJS should be evaluated for esophageal stricture and subsequent EEM development. Close follow-up, biopsy surveillance for dysplasia, endoscopic treatment, and TP53 genetic sequencing should be considered due to EEM's association with esophageal squamous cell cancer. [Extracted from the article]

A 66-year-old woman developed Stevens Johnson syndrome (SJS) while being treated with ceftriaxone for a Klebsiella Pneumoniae infection. Prior to this, she had a history of frequent nephrolithiasis and was scheduled for lithotripsy. After undergoing stone removal and stent placement, she was diagnosed with the infection and started on ceftriaxone. However, on the second day of treatment, she developed severe dryness and cracking of the oral mucosa, leading to a diagnosis of SJS. Ceftriaxone was discontinued and the woman eventually improved with the use of ciprofloxacin. [Extracted from the article]

A 6-year-old boy experienced a lack of efficacy with several medications, including desloratadine, levocetirizine, salbutamol, paracetamol, and ibuprofen, for Stevens Johnson syndrome (SJS). The boy was admitted to the hospital with fever, rash, and respiratory distress. He received various treatments, including clarithromycin, immune-globulin, and methylprednisolone, and showed some improvement before being discharged after 17 days. However, he experienced mild to moderate pain on urination for a month and developed a mild scar in his right cornea. Currently, he has been diagnosed with bronchiolitis. The lack of efficacy with the aforementioned drugs was considered due to the lack of improvement seen with them. [Extracted from the article]

A 51-year-old woman developed Stevens Johnson syndrome while being treated for hepatitis B with diammonium-glycyrrhizinate and omeprazole. She was initially admitted for acute liver failure and post-hepatitis B cirrhosis and was prescribed several medications, including omeprazole and diammonium glycyrrhizinate. She developed a rash and fever, and was readmitted to the hospital. The diagnosis of Stevens Johnson syndrome was confirmed, and her treatment with omeprazole and diammonium glycyrrhizinate was stopped. She was started on other medications and gradually showed improvement. [Extracted from the article]

In a retrospective study, a patient developed Stevens-Johnson syndrome (SJS) while being treated with cotrimoxazole. The patient experienced long-term complications such as dry eye disease and severe meibomian gland dysfunction. The study included 72 patients enrolled between October 2015 and October 2021, but specific details about the patient's age, sex, dosage, and outcome were not provided. [Extracted from the article]

A new report from Shaoxing People's Hospital discusses the rare but life-threatening skin conditions known as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The report presents a case of a 73-year-old female patient who developed SJS/TEN after taking certain medications and subsequently developed fulminant type 1 diabetes mellitus (FT1DM). The patient was treated with intravenous immunoglobulin (IVIG) and insulin, leading to recovery. The research suggests that monitoring blood glucose levels and comprehensive therapy can improve the prognosis for patients with SJS/TEN and FT1DM. [Extracted from the article]

A 55-year-old woman with a history of hypertension, diabetes, and decompensated liver failure developed Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) while being treated with rifaximin. She had started receiving rifaximin, along with other medications, for her liver failure. One week after starting the medications, she developed a rash on her inner thighs, which eventually spread and became more severe. After a skin biopsy confirmed SJS/TEN, it was determined that rifaximin was the cause. Despite treatment, her condition worsened and she died after two weeks of hospitalization. [Extracted from the article]